These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21367750)

  • 1. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
    Zauli G; Voltan R; di Iasio MG; Bosco R; Melloni E; Sana ME; Secchiero P
    Clin Cancer Res; 2011 May; 17(9):2712-24. PubMed ID: 21367750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
    Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
    Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
    Secchiero P; Voltan R; di Iasio MG; Melloni E; Tiribelli M; Zauli G
    Clin Cancer Res; 2010 Mar; 16(6):1824-33. PubMed ID: 20215548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
    di Iasio MG; Norcio A; Melloni E; Zauli G
    Invest New Drugs; 2012 Dec; 30(6):2403-6. PubMed ID: 22238073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
    Voltan R; Secchiero P; Corallini F; Zauli G
    Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
    Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
    Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
    Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
    Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.
    Celeghini C; Voltan R; Rimondi E; Gattei V; Zauli G
    Invest New Drugs; 2011 Apr; 29(2):392-5. PubMed ID: 20130960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.
    Basova P; Pospisil V; Savvulidi F; Burda P; Vargova K; Stanek L; Dluhosova M; Kuzmova E; Jonasova A; Steidl U; Laslo P; Stopka T
    Oncogene; 2014 Sep; 33(39):4735-45. PubMed ID: 24121269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-34a promotes MICB expression in hepatocytes.
    Zhou MT; Zhao C; Chen X; Zhang HC; Li G; Lou H; Huang WJ; Wei LJ; Li DW; Wu X; Zhang ZC; Liu H; Ou R; Yang WJ; Hu S; Xu Y; Tang KF
    Carcinogenesis; 2018 Dec; 39(12):1477-1487. PubMed ID: 30256916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis.
    Kiyonari S; Iimori M; Matsuoka K; Watanabe S; Morikawa-Ichinose T; Miura D; Niimi S; Saeki H; Tokunaga E; Oki E; Morita M; Kadomatsu K; Maehara Y; Kitao H
    Mol Cancer Ther; 2015 Oct; 14(10):2332-42. PubMed ID: 26208523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
    Kumamoto K; Spillare EA; Fujita K; Horikawa I; Yamashita T; Appella E; Nagashima M; Takenoshita S; Yokota J; Harris CC
    Cancer Res; 2008 May; 68(9):3193-203. PubMed ID: 18451145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-regulation of B-Myb expression by E2F1 and EGF receptor.
    Hanada N; Lo HW; Day CP; Pan Y; Nakajima Y; Hung MC
    Mol Carcinog; 2006 Jan; 45(1):10-7. PubMed ID: 16299810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
    Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G
    Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.
    Secchiero P; Rimondi E; di Iasio MG; Voltan R; Gonelli A; Zauli G
    J Cell Physiol; 2012 May; 227(5):1829-37. PubMed ID: 21732354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
    Rizzo M; Mariani L; Cavallini S; Simili M; Rainaldi G
    Nucleic Acid Ther; 2012 Aug; 22(4):283-8. PubMed ID: 22830357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.
    di Iasio MG; Zauli G
    Invest New Drugs; 2013 Apr; 31(2):458-60. PubMed ID: 23054209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.